Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of LY2603618 plus pemetrexed in previously treated advanced or metastatic non-small cell lung cancer
2009-013787-39Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rabusertib and pemetrexed in non-small cell lung cancer (NSCLC), sponsored by Eli Lilly and Company. Primary endpoint: Overall response rate. Started Sep 2009; status: completed.
02
Drugs
rabusertibpemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2009-013787-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013787-39.